Tipifarnib in Treating Patients With Myelofibrosis and Myeloid Metaplasia
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Phase II trial to study the effectiveness of tipifarnib in treating patients who have
myelofibrosis with myeloid metaplasia. Tipifarnib may stop the growth of tumor cells by
blocking the enzymes necessary for tumor cell growth.